<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metoprolol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metoprolol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Metoprolol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9645" href="/d/html/9645.html" rel="external">see "Metoprolol: Drug information"</a> and <a class="drug drug_patient" data-topicid="10864" href="/d/html/10864.html" rel="external">see "Metoprolol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709042"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Ischemic heart disease (metoprolol tartrate [oral]):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction (MI) have occurred. When discontinuing chronically administered metoprolol, particularly in patients with ischemic heart disease, gradually reduce the dosage over a period of 1 to 2 weeks and carefully monitor the patient. If angina markedly worsens or acute coronary insufficiency develops, reinstate metoprolol administration promptly, at least temporarily, and take other measures appropriate for the management of unstable angina. Warn patients against interruption or discontinuation of therapy without their health care provider's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue metoprolol therapy abruptly, even in patients treated only for hypertension.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F195796"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Kapspargo Sprinkle;</li>
<li>Lopressor;</li>
<li>Toprol XL</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867546"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AA-Metoprolol SR;</li>
<li>AG-Metoprolol-L;</li>
<li>APO-Metoprolol;</li>
<li>APO-Metoprolol Type L;</li>
<li>DOM-Metoprolol-L;</li>
<li>JAMP-Metoprolol-L;</li>
<li>Lopresor SR [DSC];</li>
<li>Lopresor [DSC];</li>
<li>Metoprolol-L;</li>
<li>PMS-Metoprolol-L;</li>
<li>RIVA-Metoprolol-L;</li>
<li>Sandoz Metoprolol SR [DSC];</li>
<li>TEVA-Metoprolol</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1054023"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antianginal Agent</span>;</li>
<li>
<span class="list-set-name">Antiarrhythmic Agent, Class II</span>;</li>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Antimigraine Agent</span>;</li>
<li>
<span class="list-set-name">Beta-Adrenergic Blocker</span></li></ul></div>
<div class="block dop drugH1Div" id="F195823"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dose should be individualized based on patient response.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86fd017b-f098-427e-b843-c16a24638f11">Heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure (dilated cardiomyopathy):</b> Limited data available: Children and Adolescents: Oral: Immediate release (metoprolol tartrate): Initial: 0.1 to 0.2 mg/kg/dose twice daily, may increase slowly (usually every 2 weeks) as needed up to 1 mg/kg/<b>day</b>; maximum daily dose: 2 mg/kg/<b>day</b> or 200 mg/<b>day</b>, whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-Park.1','lexi-content-ref-10328154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-Park.1','lexi-content-ref-10328154'])">Ref</a></span>). Dosing based on a multicenter, open-label trial in 15 pediatric patients (age range: 2.5 to 15 years, mean: 8.6 ± 1.3 years) with dilated cardiomyopathy with heart failure that failed to show improvement in left ventricular function on conventional therapy; after 23 months of metoprolol, significant increases in ejection fraction (mean: 41.1%) and fractional shortening (mean: 23.3%) were observed; the reported mean maximum daily dose was 1.1 ± 0.1 mg/kg/day (range: 0.5 to 2.3 mg/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10328154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10328154'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b>
<b>Note: </b>Guidelines do not recommend beta-blockers as initial therapy in pediatric patients; beta-blockers should be reserved for use in patients who have contraindications to preferred agents or after ≥2 preferred agents have failed in patients with hypertension and chronic kidney disease, proteinuria, or diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29192011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29192011'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release tablets (metoprolol tartrate): Children and Adolescents ≤17 years: Oral: Initial: 0.5 to 1 mg/kg/dose (maximum initial dose: 25 mg/dose) twice daily; adjust dose based on patient response; maximum daily dose: 6 mg/kg/<b>day</b> or 200 mg/<b>day</b>, whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286277','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286277','lexi-content-ref-NIH.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release sprinkle capsules or tablets (metoprolol succinate): Children ≥6 years and Adolescents: Oral: Initial: 1 mg/kg/dose once daily (maximum initial dose: 50 mg/dose); adjust dose based on patient response; maximum daily dose: 2 mg/kg/<b>day</b> or 200 mg/<b>day</b>, whichever is less; higher doses have not been studied.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="45c36cf3-bbcf-43f4-87cd-3b67344f7b1a">Syncope, vagal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Syncope, vagal:</b> Limited data available: Children ≥7 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Tilt-table test: IV: 0.1 to 0.2 mg/kg; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8438747','lexi-content-ref-8121741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8438747','lexi-content-ref-8121741'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Chronic treatment: Oral: Immediate release (metoprolol tartrate): 0.5 to 1 mg/kg/dose two times daily; maximum daily dose: 6 mg/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-8438747','lexi-content-ref-8121741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-8438747','lexi-content-ref-8121741'])">Ref</a></span>). Dosing based on two studies: In one study, oral metoprolol was initiated at doses of 0.8 to 2.8 mg/kg/day in 15 patients (8 to 20 years of age) after showing response to tilt-table testing. During follow up, a total of 6 patients discontinued therapy due to recurrent syncope or adverse events including irritability/moodiness, severe depression, and severe nausea (dose ranged in this group from 1.6 to 2.8 mg/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8438747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8438747'])">Ref</a></span>); in another study, oral doses of 1 to 2 mg/kg/day, rounded to the nearest 25 mg/day and divided into 2 doses daily were used in 19 patients (7 to 18 years of age) with unexplained syncope; the mean effective dose was 1.5 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8121741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8121741'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130081"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents: No dosage adjustment necessary</p></div>
<div class="block dohp drugH1Div" id="F51130082"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents: There are no specific dosage adjustments provided in the manufacturer's labeling. Consider initiating with reduced doses and gradual dosage titration due to extensive hepatic metabolism<b>.</b></p></div>
<div class="block doa drugH1Div" id="F195801"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9645" href="/d/html/9645.html" rel="external">see "Metoprolol: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c263a8d4-f2ef-49a8-a963-6b87a475dbec">Angina</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For vasospastic angina, beta-blockers are not recommended; calcium channel blockers and nitrates are preferred. For nonvasospastic angina, guidelines recommend titrating dose to a resting heart rate of 55 to 60 beats per minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211'])">Ref</a></span>), while other experts recommend target of 60 to 70 beats per minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kannam.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kannam.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release (metoprolol tartrate):</i>
<b>Oral:</b> Initial: 50 mg twice daily; may increase dose at weekly intervals to desired effect; usual dosage range: 50 to 200 mg twice daily; maximum dose: 400 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release (metoprolol succinate):</i>
<b>Oral:</b> Initial: 100 mg once daily; may increase dose at weekly intervals to desired effect; maximum dose: 400 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For microvascular angina, some experts start with 50 mg/day (divided twice daily for the immediate-release formulation or once daily for the extended-release formulation) and increase to 100 to 200 mg/day as needed to control symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chaudhary.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chaudhary.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9998ecf1-cec8-46bc-96a5-5289902ef8d0">Atrial fibrillation/flutter</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation/flutter (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Initiate cautiously in patients with concomitant heart failure at a dose that is appropriate for that indication. Avoid initiating or up-titrating therapy in patients with decompensated heart failure; for unstable patients, electrical cardioversion is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24685669','lexi-content-ref-33081529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24685669','lexi-content-ref-33081529'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute ventricular rate control: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2.5 to 5 mg over 2 minutes; repeat dose every 5 minutes as needed; maximum total dose: 15 mg. <b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance of ventricular rate control: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release (metoprolol tartrate):</i>
<b>Oral:</b> Initial: 25 mg twice daily; increase dose gradually as tolerated to achieve ventricular rate control up to 100 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24685669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24685669'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release (metoprolol succinate):</i>
<b>Oral:</b> Initial: 50 mg once daily; increase dose gradually as tolerated to achieve ventricular rate control up to 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24685669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24685669'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Atrial fibrillation prevention after cardiac surgery: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Initiate prior to surgery (preferentially at least 48 hours before) or postoperatively when hemodynamically stable. Continue therapy at least until the first postoperative visit in patients with no other indication for beta-blocker therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lee.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lee.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release (metoprolol tartrate)</i>
<i>:</i>
<b>Oral:</b> Initial: 25 to 50 mg twice daily; titrate based on daily evaluation of hemodynamic response to the maximally tolerated dose; maximum dose: 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17499863','lexi-content-ref-17765616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17499863','lexi-content-ref-17765616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release (metoprolol succinate):</i>
<b>Oral:</b> Initial: 50 mg once daily; titrate based on daily evaluation of hemodynamic response to the maximally tolerated dose; maximum dose: 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23232844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23232844'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b43376ec-cceb-40f9-ad1e-9137f312af09">Heart failure with reduced ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Initiate only in stable, euvolemic patients. In hospitalized patients, volume status should be optimized and IV diuretics, IV vasodilators, and IV inotropic agents successfully discontinued prior to initiating therapy. Use caution when initiating in patients with NYHA class IV symptoms or recent heart failure exacerbation (particularly in those who required inotropes during their hospital course) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release (metoprolol succinate):</i>
<b>Oral:</b> Initial: 12.5 to 25 mg once daily; up-titrate gradually (eg, doubling the dose every ≥1 to 2 weeks) to a target dose of 200 mg once daily while monitoring for signs and symptoms of heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-10376614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-10376614'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Not recommended in the absence of specific comorbidities (eg, ischemic heart disease, heart failure with reduced ejection fraction, arrhythmia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133354'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release (metoprolol tartrate):</i>
<b>Oral:</b> Initial: 50 mg twice daily; titrate at weekly (or longer) intervals as needed based on patient response; maximum dose: 400 mg/day; usual dosage range: 100 to 200 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133354'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release (metoprolol succinate):</i>
<b>Oral:</b> Initial: 25 to 100 mg once daily; titrate at weekly (or longer) intervals as needed based on patient response; maximum dose: 400 mg/day; usual dosage range: 50 to 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133354'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683d5204-2f9a-4f90-86f2-dc2acc899423">Migraine, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An adequate trial for assessment of effect is considered to be at least 2 to 3 months at a therapeutic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release (metoprolol tartrate)</i>
<i>:</i>
<b>Oral:</b> Initial: 25 mg twice daily; titrate slowly (eg, every 1 to 2 weeks) based on patient response and tolerability up to 200 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22683887','lexi-content-ref-11422094','lexi-content-ref-18184294','lexi-content-ref-Schwedt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22683887','lexi-content-ref-11422094','lexi-content-ref-18184294','lexi-content-ref-Schwedt.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="51b05bef-6600-468e-9957-c474e5eda739">Myocardial infarction, early treatment and secondary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myocardial infarction, early treatment and secondary prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An <b>oral</b> beta-blocker is recommended within the first 24 hours for most patients. Patients who did not receive a beta-blocker within 24 hours of myocardial infarction should be reevaluated for secondary prevention at a later date. The optimal duration of therapy is unknown; treat for a minimum of 3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note</b>: Small doses of <b>IV </b>metoprolol at the time of presentation may be considered for ST-elevation myocardial infarction (STEMI) patients with hypertension or ongoing ischemia if no contraindications exist.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 5 mg; repeat dose every 5 minutes for up to 3 doses as needed based on heart rate and blood pressure; maximum total dose: 15 mg; begin oral therapy 15 to 30 minutes after the last IV dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-16271643','lexi-content-ref-Rosenson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-16271643','lexi-content-ref-Rosenson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release (metoprolol tartrate)</i>: Initial: 25 to 50 mg every 6 to 12 hours in the acute setting; may consider a lower starting dose of 12.5 mg every 6 to 12 hours when there is concern for adverse effects; for outpatients, transition to twice-daily dosing of metoprolol tartrate (immediate release) or to daily metoprolol succinate (extended release); titrate dose based on heart rate and blood pressure as tolerated up to a maximum dose of 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-Rosenson.1','lexi-content-ref-Simons.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-Rosenson.1','lexi-content-ref-Simons.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release (metoprolol succinate)</i>: Initial: 25 to 50 mg once daily; titrate dose based on heart rate and blood pressure as tolerated up to 200 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosenson.1','lexi-content-ref-Simons.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosenson.1','lexi-content-ref-Simons.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f882e79-d62c-4b63-bf32-63cd49609f40">Supraventricular tachycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Supraventricular tachycardia (eg, atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, focal atrial tachycardia, multifocal atrial tachycardia) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for hemodynamically stable patients if vagal maneuvers and/or adenosine are unsuccessful. Do <b>not</b> use in patients with preexcitation associated with an accessory pathway, as this can lead to ventricular arrhythmias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute treatment:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2.5 to 5 mg over 2 minutes; repeat dose every 5 minutes as needed; maximum total dose: 15 mg. <b>Note:</b> Initiate cautiously in patients with concomitant heart failure. Avoid in patients with decompensated heart failure (electrical cardioversion preferred) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259','lexi-content-ref-20956224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259','lexi-content-ref-20956224'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance therapy: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release (metoprolol tartrate):</i>
<b>Oral:</b> Initial: 25 mg twice daily; maximum dose: 400 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release (metoprolol succinate):</i>
<b>Oral:</b> Initial: 50 mg once daily; maximum dose: 400 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63559ecb-74fc-4e35-b0bd-95b480b146f7">Thyrotoxicosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyrotoxicosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note</b>: For control of cardiovascular effects until euthyroidism established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release (metoprolol tartrate):</i>
<b>Oral:</b> 25 to 50 mg every 8 to 12 hours; may also consider administering an equivalent dose of the once-daily ER formulation (metoprolol succinate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f42c553-e8c4-4b54-98fb-e270b999dc6b">Ventricular arrhythmias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular arrhythmias (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sustained ventricular tachycardia, incessant ventricular tachycardia, or electric storm (hemodynamically stable):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Beta-blockers are generally administered in addition to an antiarrhythmic drug (eg, amiodarone) for these indications. A beta-blocker is also used to reduce shocks in patients who receive an implantable cardioverter defibrillator for these indications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731'])">Ref</a></span>); propranolol may be the preferred beta-blocker in these situations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29699616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29699616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Acute ventricular tachycardia:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 5 mg every 5 minutes up to 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Prevention of ventricular arrhythmias</i>
<i>:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Immediate release (metoprolol tartrate): </i>
<b>Oral:</b> Initial: 12.5 to 25 mg twice daily; increase as needed based on patient response; maximum dose: 200 mg/day in 2 or 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12494613','lexi-content-ref-10942742','lexi-content-ref-9761084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12494613','lexi-content-ref-10942742','lexi-content-ref-9761084'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Extended release (metoprolol succinate):</i>
<b>Oral:</b> 25 to 100 mg 1 to 2 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nonsustained ventricular tachycardia or ventricular premature beats, symptomatic:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release (metoprolol tartrate): </i>
<b>Oral:</b> 50 to 200 mg/day in 2 or 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Zimetbaum.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Zimetbaum.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release (metoprolol succinate):</i>
<b>Oral:</b> 25 to 100 mg 1 to 2 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Switching dosage forms:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching from immediate release (metoprolol tartrate) to extended release (metoprolol succinate):</i> The same total daily dose of metoprolol should be used. Metoprolol tartrate is typically administered in 2 to 3 divided daily doses and metoprolol succinate is administered once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching between oral and intravenous dosage forms:</i> In most cases, equivalent beta-blocking effect is achieved when a 2.5:1 (Oral:IV) ratio is used. However, in one bioavailability study of healthy volunteers (N=5), the range of Oral:IV conversion ratios was approximately 2:1 to 5:1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4155762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4155762'])">Ref</a></span>). Therefore, patient variability may exist and a specific ratio may not apply to all patients, especially if comorbid conditions are present. The estimated equivalent IV total daily dose should be divided into 4 equal doses. For example, if a patient is receiving a chronic oral dose of metoprolol tartrate 25 mg twice daily (total daily dose of 50 mg), this could translate to a range of 2.5 mg IV every 6 hours (based on a 5:1 ratio) to 5 mg IV every 6 hours (based on a 2.5:1 ratio). Recognizing that patients receiving larger chronic oral doses should not automatically be converted to a large IV dose, consideration should be given to further reducing the initial IV dose and basing subsequent doses on the clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12561664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12561664'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990496"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7363533','lexi-content-ref-6102500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7363533','lexi-content-ref-6102500'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (metabolites): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7363534']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7363534'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987788"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling. Consider initiating with reduced doses and gradual dosage titration due to extensive hepatic metabolism.</p></div>
<div class="block arsc drugH1Div" id="F54485815"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bradyarrhythmias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may cause <b>bradycardia, sinus pause,</b>
<b>first-degree atrioventricular</b> (AV) <b>block</b>, second-degree atrioventricular block, or complete heart block (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162','lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162','lexi-content-ref-15234417'])">Ref</a></span>). At maintenance dosing, second- or third-degree AV block are less likely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2450898'])">Ref</a></span>). Beta-blocking agents with intrinsic sympathomimetic activity (eg, pindolol) may cause fewer AV conduction abnormalities than those without intrinsic sympathomimetic activity (eg, metoprolol) due to their partial agonist effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2895072','lexi-content-ref-1977302','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2895072','lexi-content-ref-1977302','lexi-content-ref-2450898'])">Ref</a></span>). In most cases (up to 72%), AV block associated with a beta-blocker will resolve upon discontinuation; however, there are reported cases of recurrent AV block and nearly 50% of patients with more severe AV block may require a permanent pacemaker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22530749','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22530749','lexi-content-ref-32929996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; related to the pharmacologic action. Blockade of cardiac beta-1 adrenergic receptors results in slowed conduction and prolongation in the refractory period of the AV node. Slowing of AV conduction can lead to AV block (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162','lexi-content-ref-2450898','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162','lexi-content-ref-2450898','lexi-content-ref-32929996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; one study included patients who were on beta-blocker for more than one month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>); however, other studies noted prolongation of the PR interval or AV nodal refractory period occurring anywhere from one dose to several days following treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897302','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897302','lexi-content-ref-2450898'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Impaired AV node conduction or sinus node dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Acute myocardial infarction (MI) (especially inferior and posterior MI) or heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29766868']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29766868'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concurrent use of other agents that impair AV nodal conduction (eg, non-dihydropyridine calcium channel blockers, digoxin, ivabradine, select antiarrhythmic agents) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bronchospasm</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective beta-blockers (eg, metoprolol) have a lower risk of <b>bronchospasm</b> compared to non-cardioselective beta-blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15579370','lexi-content-ref-27390282','lexi-content-ref-24202435','lexi-content-ref-6344309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15579370','lexi-content-ref-27390282','lexi-content-ref-24202435','lexi-content-ref-6344309'])">Ref</a></span>). Concurrent use of inhaled bronchodilators and/or corticosteroids are protective against beta-blocker-induced bronchospasm in patients with COPD or asthma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12490274','lexi-content-ref-27390282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12490274','lexi-content-ref-27390282'])">Ref</a></span>). Bronchospasm is reversible upon discontinuation or use of bronchodilators (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2439802']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2439802'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to pharmacologic action. Beta-blocking agents can lead to airway smooth muscle constriction by antagonism of beta-2 receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15579370','lexi-content-ref-27390282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15579370','lexi-content-ref-27390282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; reports suggest that single doses or acute use are more likely to cause changes in FEV<sub>1</sub> compared to chronic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24202435','lexi-content-ref-12519582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24202435','lexi-content-ref-12519582'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Moderate to severe COPD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31633896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31633896'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Acute use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24202435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24202435'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may cause reversible CNS effects such as <b>fatigue</b>, <b>sleep disturbance, insomnia</b>, vivid dreams, and memory impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714','lexi-content-ref-15288162','lexi-content-ref-1969642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714','lexi-content-ref-15288162','lexi-content-ref-1969642'])">Ref</a></span>). Sexual disorders may occur; however, patients who require beta-blocker therapy have risk factors for erectile dysfunction (eg, coronary artery disease, heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29746858','lexi-content-ref-12117400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29746858','lexi-content-ref-12117400'])">Ref</a></span>). In addition, there may be a psychosomatic component (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18654082','lexi-content-ref-14585251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18654082','lexi-content-ref-14585251'])">Ref</a></span>). Lipophilic beta-blockers (such as metoprolol, which is moderately lipophilic) penetrate the blood-brain barrier to a greater extent than hydrophilic beta-blockers, possibly leading to a greater incidence of CNS effects; however, other studies have refuted this theory (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4054193','lexi-content-ref-1969714','lexi-content-ref-2891122','lexi-content-ref-1969642','lexi-content-ref-2865153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4054193','lexi-content-ref-1969714','lexi-content-ref-2891122','lexi-content-ref-1969642','lexi-content-ref-2865153'])">Ref</a></span>). CNS effects generally resolve with dose reduction or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; exact mechanism is not fully understood. Proposed mechanisms include presence of beta receptors in the brain, affinity and in some instances, inhibition of beta-blocking agents towards serotonin (5-HT) receptors in the brain (affecting mood and sleep), and beta-blocker-induced decreases in central sympathetic output (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8956349','lexi-content-ref-2865151','lexi-content-ref-2878741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8956349','lexi-content-ref-2865151','lexi-content-ref-2878741'])">Ref</a></span>). Beta-1 blockade may also impact sleep by blocking sympathetic signaling to the pineal gland, resulting in suppression of nighttime levels of melatonin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23024438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23024438'])">Ref</a></span>). Beta-blockers may cause erectile dysfunction through decreased sympathetic nervous system output and subsequent decreases in luteinizing hormone secretion and testosterone stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24155101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24155101'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; CNS effects often occur within the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher starting doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969642'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Potentiation/masking of hypoglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may worsen, prolong, or cause hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749','lexi-content-ref-6376011','lexi-content-ref-2861072','lexi-content-ref-vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749','lexi-content-ref-6376011','lexi-content-ref-2861072','lexi-content-ref-vue.1'])">Ref</a></span>). Additionally, beta-blockers may mask symptoms of hypoglycemia (tremor, irritability, palpitations), making diaphoresis the only symptom unaffected by beta-blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-vue.1'])">Ref</a></span>). It is unclear if non-selective or selective beta-blockers are more likely to cause hypoglycemia as data are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749','lexi-content-ref-20067434','lexi-content-ref-85053','lexi-content-ref-6376017','lexi-content-ref-vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749','lexi-content-ref-20067434','lexi-content-ref-85053','lexi-content-ref-6376017','lexi-content-ref-vue.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Beta-blockers inhibit hepatic gluconeogenesis and glycogenolysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2861072','lexi-content-ref-vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2861072','lexi-content-ref-vue.1'])">Ref</a></span>). Beta-blockers also reduce activation of the sympathetic nervous system, therefore masking hypoglycemic symptoms that are catecholamine-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-vue.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; blood glucose recovery was significantly reduced following one dose or one day of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6376011','lexi-content-ref-85053','lexi-content-ref-6376017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6376011','lexi-content-ref-85053','lexi-content-ref-6376017'])">Ref</a></span>). In another study, episodes of severe hypoglycemia were reported over the course of 4 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28559400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28559400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Insulin-dependent diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6376011','lexi-content-ref-2861072','lexi-content-ref-6376017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6376011','lexi-content-ref-2861072','lexi-content-ref-6376017'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type 2 diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28559400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28559400'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients who are hospitalized and not requiring basal insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blocker therapy should not be withdrawn abruptly, but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia in patients with underlying cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874','lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874','lexi-content-ref-37093'])">Ref</a></span>). Some studies have found an increase in propensity-adjusted mortality and cardiovascular events; however, one study did not find changes in infarct size and left ventricular function when beta-blocker was abruptly withdrawn in patients with myocardial infarction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3009050','lexi-content-ref-18617067','lexi-content-ref-1968518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3009050','lexi-content-ref-18617067','lexi-content-ref-1968518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-dependent; related to the pharmacologic action. Beta blockade causes upregulation of beta-receptors, enhanced receptor sensitivity, and decreased sympathetic nervous system response. Abrupt withdrawal leads to a transient sympathetic hyper-response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874','lexi-content-ref-436208','lexi-content-ref-6125187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874','lexi-content-ref-436208','lexi-content-ref-6125187'])">Ref</a></span>). Another proposed mechanism involves increased platelet aggregability to epinephrine and thrombin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874','lexi-content-ref-668066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874','lexi-content-ref-668066'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid/varied and transient; increases in heart rate and blood pressure appear 24 hours after abrupt withdrawal, peak after 48 hours, and subside after 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093'])">Ref</a></span>). Anginal symptoms reported to begin 12 to 24 hours after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1244260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1244260'])">Ref</a></span>). Development of adverse reactions also reported to occur 1 to 21 days after withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-668066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-668066'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt withdrawal in chronic users (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Past medical history of coronary artery disease (including chronic stable angina) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897781','lexi-content-ref-2883874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897781','lexi-content-ref-2883874'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Past medical history of hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093','lexi-content-ref-1968518','lexi-content-ref-6125187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093','lexi-content-ref-1968518','lexi-content-ref-6125187'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F195759"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Cardiovascular: Bradycardia (including sinus pause: 2% to 16%)<span class="lexi-table-link-container"> (<a aria-label="Bradycardia table link" class="lexi-table-link" data-table-id="lexi-content-bradycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bradycardia')">table 1</a>)</span><span class="table-link" style="display:none;">Bradycardia</span>, hypotension (1% to 27%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bradycardia" frame="border" id="lexi-content-bradycardia" rules="all">
<caption style="text-align:center;">
<b>Metoprolol: Adverse Reaction: Bradycardia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Metoprolol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Metoprolol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cardiac failure</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,990</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,001</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Myocardial infarction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial insufficiency (usually Raynaud type: 1%), cold extremity (1%), first-degree atrioventricular block (5%)<span class="lexi-table-link-container"> (<a aria-label="First Degree Atrioventricular Block table link" class="lexi-table-link" data-table-id="lexi-content-first-degree-atrioventricular-block" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-first-degree-atrioventricular-block')">table 2</a>)</span><span class="table-link" style="display:none;">First Degree Atrioventricular Block</span>, heart failure (1%), palpitations (1%), peripheral edema (1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="First Degree Atrioventricular Block" frame="border" id="lexi-content-first-degree-atrioventricular-block" rules="all">
<caption style="text-align:center;">
<b>Metoprolol: Adverse Reaction: First-Degree Atrioventricular Block</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Metoprolol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Myocardial infarction</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Gangrene of skin and/or subcutaneous tissues (1%), pruritus (5%), skin rash (&gt;2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (1%), diarrhea (&gt;2% to 5%), flatulence (1%), heartburn (1%), nausea (≤1%), stomach pain (1%), xerostomia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident (1%), depression (&gt;2% to 5%), dizziness (2% to 10%), fatigue (1% to 10%), vertigo (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (1%), dyspnea (≤3%), wheezing (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Peyronie disease</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, arthritis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Claudication</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exacerbation of psoriasis (Yilmaz 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Unstable diabetes, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Retroperitoneal fibrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Sleep disturbance (McAnish 1990), temporary amnesia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous pemphigoid (Perry 2005), diaphoresis, erythroderma (Doyon 2017), lichenoid dermatitis (Nguyen 2011), pemphigoid-like lesion (Patel 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased HDL cholesterol (Day 1982: Rössner 1983), decreased libido (Ko 2002), increased serum triglycerides (Day 1982; Kim 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction (Cocco 2009), impotence (Ko 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic insufficiency (Philips 2017), hepatitis (Larrey 1988), increased serum alkaline phosphatase (Larrey 1988), increased serum transaminases (Larrey 1988), jaundice (Hansen 2017; Phillis 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion (Fisher 2002), drowsiness, hallucination (Fisher 2002; Sirois 2006), headache (Nicpon 2006), insomnia (McAnish 1990), nervousness (Ahmed 2010), nightmares (Ahmed 2010), paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthropathy (psoriatic) (Tatu 2017), musculoskeletal pain (Snyder 1991)</p></div>
<div class="block coi drugH1Div" id="F195775"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to metoprolol, any component of the formulation, or other beta-blockers; second- or third-degree heart block (except in patients with a functioning artificial pacemaker).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Additional contraindications are formulation and/or indication specific.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate-release tablets/injectable formulation:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hypertension and angina (oral only):</i> Sinus bradycardia; cardiogenic shock; overt heart failure; sick sinus syndrome (except in patients with a functioning artificial pacemaker); severe peripheral arterial circulatory disorders.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Myocardial infarction (oral and injection):</i> Severe sinus bradycardia (heart rate &lt;45 beats/minute); significant first-degree heart block (P-R interval ≥0.24 seconds) (except in patients with a functioning artificial pacemaker); systolic blood pressure &lt;100 mm Hg; moderate to severe cardiac failure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended-release formulation:</b> Severe bradycardia, cardiogenic shock; decompensated heart failure; sick sinus syndrome (except in patients with a functioning artificial pacemaker).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Cor pulmonale; untreated pheochromocytoma; asthma and other obstructive respiratory disease (injection only); concomitant use with anesthesia agents that cause myocardial depression.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F195756"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse events:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated allergen challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure with reduced ejection fraction: Stabilize patients on heart failure regimen prior to initiation or titration of beta-blocker. Beta-blocker therapy should be initiated at very low doses with gradual and careful titration. Worsening heart failure or fluid retention may occur during upward titration; dose reduction and/or slower titration may be necessary. Adjustment of other medications (angiotensin-converting enzyme inhibitors and/or diuretics) may be required. Only the ER formulation is indicated for use in heart failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use beta-blockers with caution in patients with myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral vascular disease (PVD) and Raynaud disease: May precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud disease. Use with caution and monitor for progression of arterial obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prinzmetal variant angina: Beta-blockers without alpha1-adrenergic receptor blocking activity should be avoided in patients with Prinzmetal variant angina because unopposed alpha1-adrenergic receptors mediate coronary vasoconstriction and can worsen anginal symptoms (Mayer 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">• Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Supraventricular tachycardia (SVT): If antidromic atrioventricular reentrant tachycardia (AVRT) or pre-excited atrial fibrillation is suspected, avoid AV node-specific blocking drugs (eg, adenosine, diltiazem, verapamil, digoxin, beta-blockers). For these types of SVT enhanced antegrade conduction from atria to ventricles may occur through an accessory pathway leading to ventricular arrhythmias if the AV node is blocked. It is safe to use AV node-specific blocking drugs for orthodromic AVRT because antegrade conduction occurs through the AV node and only retrograde conduction (from ventricles to atria) occurs through the accessory pathway.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm. Alterations in thyroid function tests may be observed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abrupt withdrawal: Abrupt withdrawal may exacerbate underlying conditions, such as angina pectoris, sinus tachycardia, hypertension, and arrhythmias; cases of myocardial infarction have also occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878547"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block dosfc drugH1Div" id="F51089975"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">The extended release metoprolol succinate products' strengths are expressed as metoprolol tartrate equivalents.</p></div>
<div class="block foc drugH1Div" id="F195767"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule ER 24 Hour Sprinkle, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kapspargo Sprinkle: 25 mg, 50 mg, 100 mg, 200 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as tartrate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lopressor: 50 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lopressor: 100 mg [scored; contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as succinate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toprol XL: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toprol XL: 25 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toprol XL: 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toprol XL: 50 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toprol XL: 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toprol XL: 100 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toprol XL: 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toprol XL: 200 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg, 200 mg</p></div>
<div class="block geq drugH1Div" id="F195752"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F195777"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Sprinkle</b> (Kapspargo Sprinkle Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $2.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $2.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $4.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Metoprolol Tartrate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $0.19 - $0.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Metoprolol Succinate ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.14 - $1.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.12 - $1.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.31 - $2.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.30 - $3.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Toprol XL Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $1.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $3.77</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lopressor Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $3.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $4.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Metoprolol Tartrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.24 - $0.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $1.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.13 - $0.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $2.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867547"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lopresor: 5 mg/5 mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (5 mL); 5 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lopresor SR: 100 mg [DSC], 200 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg</p></div>
<div class="block exp drugH1Div" id="F195773"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>10 mg/mL Oral Suspension (ASHP Standard Concentration) (ASHP 2017)</b></p>
<p style="text-indent:-2em;margin-left:2em;">A 10 mg/mL oral suspension may be made with metoprolol tartrate tablets and one of three different vehicles (cherry syrup; a 1:1 mixture of Ora-Sweet and Ora-Plus; or a 1:1 mixture of Ora-Sweet SF and Ora-Plus). Crush twelve 100 mg tablets in a mortar and reduce to a fine powder. Add 20 mL of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label "shake well" and "protect from light". Stable for 60 days.</p>
<div class="reference">Allen LV Jr and Erickson MA 3rd, "Stability of Labetalol Hydrochloride, Metoprolol Tartrate, Verapamil Hydrochloride, and Spironolactone With Hydrochlorothiazide in Extemporaneously Compounded Oral Liquids," <i>Am J Health Syst Pharm</i>, 1996, 53(19):2304-9.<span class="pubmed-id">8893069</span></div>
</div>
<div class="block admp drugH1Div" id="F52613320"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release (metoprolol tartrate): Tablets: Administer with food or immediately after meals; swallow whole with a glass of water.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release (metoprolol succinate):</p>
<p style="text-indent:-2em;margin-left:6em;">Sprinkle capsules: Administer without regard to meals; may be swallowed whole or the capsule may be opened and the contents sprinkled on small amount (1 teaspoonful) of soft food (eg, pudding, applesauce, yogurt) and used within 60 minutes of preparation; do not store drug-food mixture for later use.</p>
<p style="text-indent:-2em;margin-left:8em;">Nasogastric tube administration: Open capsule and add contents to an all plastic oral syringe and add 15 mL of water; gently shake syringe for ~10 seconds to disperse granules. Administer immediately through ≥12-french nasogastric tube. No granules should remain in syringe; rinse syringe with additional water if necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablets: May be administered without regard to meals; Toprol-XL tablets are scored and may be divided; do not chew or crush the half or whole tablets; swallow whole. Do not chew, crush, or break generic nonscored extended-release tablets; swallow whole.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV dose is much smaller than oral dose. When administered acutely for cardiac treatment, monitor ECG and blood pressure</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents: Limited data available; dose was administered over 10 minutes in one study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8438747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8438747'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: May administer undiluted by rapid infusion (IV push) over 1 minute. May also be administered by slow infusion (ie, 5 to 10 mg of metoprolol in 50 mL of fluid) over ~30 to 60 minutes during less urgent situations (eg, substitution for oral metoprolol).</p></div>
<div class="block adm drugH1Div" id="F195771"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release (metoprolol tartrate): Administer with or immediately following meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release (metoprolol succinate): According to the manufacturer, it is preferable to administer with or immediately following meals; however, may administer without regard to meals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12708950','lexi-content-ref-2257873','lexi-content-ref-12548073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12708950','lexi-content-ref-2257873','lexi-content-ref-12548073'])">Ref</a></span>). May divide tablets in half; do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER tablet (metoprolol succinate) may be divided in half but not crushed or chewed. IR tablet, oral solution, and injectable formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, selection of IR formulation or alternative therapy is advised for cardiovascular and other high-risk labeled and off-label indications.</p>
<p style="text-indent:-2em;margin-left:6em;">Sprinkle capsule: May be swallowed whole or the capsule may be opened and contents sprinkled on a small amount (1 teaspoonful) of soft food (eg, applesauce, pudding, or yogurt) to be used within 60 minutes (do not store for future use).</p>
<p style="text-indent:-2em;margin-left:8em;">Nasogastric tube administration: Open capsule and add contents to an all plastic oral tip syringe; add 15 mL of water. Gently shake the syringe for ~10 seconds. Immediately deliver mixture through a ≥12 French nasogastric tube. No granules should remain in the syringe; rinse syringe with additional water if necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> May administer undiluted by rapid infusion (IV push) over 1 minute for acute treatment. May also be administered by slow infusion (ie, 5 to 10 mg of metoprolol in 50 mL of fluid) over ~30 to 60 minutes during less urgent situations (eg, substitution for oral metoprolol).</p></div>
<div class="block sts drugH1Div" id="F195790"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light and heat.</p>
<p style="text-indent:-2em;margin-left:2em;">Sprinkle capsules: Store at 20°C to 25°C (68°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from moisture.</p></div>
<div class="block usep drugH1Div" id="F53567827"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate-release tablets and injection: Treatment of hypertension, alone or in combination with other agents, angina pectoris, and hemodynamically-stable acute myocardial infarction (to reduce cardiovascular mortality) (All indications: FDA approved in adults); has also been used in the management of patients with heart failure from dilated cardiomyopathy, hypertrophic cardiomyopathy, and for the treatment of syncope.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended-release sprinkle capsules and tablets: Treatment of hypertension, alone or in combination with other agents (FDA approved in ages ≥6 years and adults); angina pectoris (FDA approved in adults); and patients with heart failure (stable NYHA Class II or III) already receiving ACE inhibitors, diuretics, and/or digoxin (to reduce mortality/hospitalization) (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F195857"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lopressor may be confused with Lyrica</p>
<p style="text-indent:-2em;margin-left:4em;">Metoprolol may be confused with metaproterenol, metoclopramide, metOLazone, miSOPROStol</p>
<p style="text-indent:-2em;margin-left:4em;">Metoprolol succinate may be confused with metoprolol tartrate</p>
<p style="text-indent:-2em;margin-left:4em;">Toprol-XL may be confused with Tegretol, Tegretol XR, Topamax</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F195842"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F195761"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Beta-Blockers (Beta1 Selective) may enhance the hypoglycemic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: Beta-Blockers may enhance the adverse/toxic effect of Cannabis. Specifically, the risk of hypoglycemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Metoprolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Metoprolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOBUTamine: Beta-Blockers may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose. Increase monitoring for clinical response and adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): Beta-Blockers may diminish the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Nasal): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Oral Inhalation): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of EPINEPHrine (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epinephrine (Racemic): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of Epinephrine (Racemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of EPINEPHrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may diminish the therapeutic effect of Etilefrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etofylline: Beta-Blockers may diminish the therapeutic effect of Etofylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers.  Management: Consider alternatives to either grass pollen allergen extract (5 grass extract) or beta-blockers in patients with indications for both agents.  Canadian product labeling specifically lists this combination as contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxychloroquine: May increase the serum concentration of Metoprolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: Beta-Blockers may diminish the therapeutic effect of Isoproterenol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: May enhance the hypotensive effect of Metoprolol. Metoprolol may decrease the serum concentration of Lercanidipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: Beta-Blockers may enhance the adverse/toxic effect of Mavacamten. Specifically, negative inotropic effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: May diminish the antihypertensive effect of Metoprolol. Mirabegron may increase the serum concentration of Metoprolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Beta-Blockers may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: May enhance the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PENTobarbital: May enhance the hypotensive effect of Metoprolol. PENTobarbital may decrease the serum concentration of Metoprolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May enhance the bradycardic effect of Beta-Blockers. Reserpine may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Metoprolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Beta-Blockers may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: Beta-Blockers may diminish the therapeutic effect of Tasimelteon.  Management: Consider avoiding nighttime administration of beta-blockers during tasimelteon therapy due to the potential for reduced tasimelteon efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">White Birch Allergen Extract: Beta-Blockers may enhance the adverse/toxic effect of White Birch Allergen Extract. Specifically, beta-blockers may reduce the effectiveness of beta-agonists that may be required to treat systemic reactions to white birch allergen extract. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F195792"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food increases absorption. Metoprolol serum levels may be increased if taken with food. Management: Take immediate release tartrate tablets with food; succinate can be taken with or without food.</p></div>
<div class="block rep_considerations drugH1Div" id="F56813566"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Metoprolol is generally not a preferred agent for use in pregnant patients (ACC/AHA [Whelton 2018]; ACOG 2019); however, use may be considered (ESC [Cífková 2020]; SOGC [Magee 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Metoprolol may be continued for the treatment of heart failure in patients planning to become pregnant; treatment should be made as part of a shared decision-making process (AHA/ACC/HFSA [Heidenreich 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Metoprolol is effective for prevention of migraines. In general, preventive treatment for migraine in patients trying to become pregnant should be avoided. Options for patients planning a pregnancy should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data and needs of the patient should pregnancy occur. A gradual discontinuation of preventive medications is generally preferred when the decision is made to stop treatment prior to conception (ACOG 2022; AHS [Ailani 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Erectile dysfunction and inhibition of sperm motility are noted in product labeling following use of metoprolol. As a class, outcomes from available studies evaluating beta-blockers and sexual dysfunction are inconsistent, and the negative effects on erectile function and libido are considered controversial. A clear relationship between use of beta-blockers and erectile dysfunction has not been established. Hypertension itself is associated with erectile dysfunction. Patients on a beta-blocker presenting with sexual dysfunction should be evaluated for underlying disease (Farmakis 2021; Levine 2012; Semet 2017; Terentes-Printzios 2022; Viigimaa 2020).</p></div>
<div class="block pri drugH1Div" id="F195778"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Metoprolol and the metabolite alpha-hydroxymetoprolol cross the placenta (Lindeberg 1987; Ryu 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Exposure to beta-blockers during pregnancy may increase the risk for adverse events in the neonate. If maternal use of a beta-blocker is needed, monitor fetal growth during pregnancy; monitor the newborn for 48 hours after delivery for bradycardia, hypoglycemia, and respiratory depression (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetics of metoprolol may be changed during pregnancy; the degree of changes may be dependent upon maternal CYP2D6 genotype (Ryu 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of hypertension is initiated during pregnancy, agents other than metoprolol may be preferred (ACOG 2019); however, use may be considered (ESC [Cífková 2020]; SOGC [Magee 2022]). Metoprolol may be continued for the treatment of heart failure in pregnant patients; treatment should be made as part of a shared decision-making process (AHA/ACC/HFSA [Heidenreich 2022]). Metoprolol may be used for the treatment of maternal ventricular arrhythmias, atrial fibrillation/atrial flutter, or supraventricular tachycardia during pregnancy; consult current guidelines for specific recommendations (ACC/AHA/HRS [Page 2016]; ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">In general, preventive treatment for migraine should be avoided during pregnancy. Options for pregnant patients should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data, the potential for adverse maternal and fetal events, and needs of the patient (ACOG 2022; AHS [Ailani 2021]). If preventive therapy is needed, beta-blockers may be considered (ACOG 2022). Based on available data, metoprolol may be used if prophylaxis of migraine is needed in pregnant patients; it should be discontinued 2 to 3 days prior to delivery to decrease the risk of adverse events to the fetus/neonate and potential reductions in uterine contraction (CHS [Pringsheim 2012]).</p></div>
<div class="block mopp drugH1Div" id="F53567828"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Blood pressure, heart rate and rhythm</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">Acute cardiac treatment: Monitor ECG, heart rate, and blood pressure with IV administration</p>
<p style="text-indent:-2em;margin-left:4em;">IV use in a nonemergency situation: Necessary monitoring for surgical patients who are unable to take oral beta-blockers (because of prolonged ileus) has not been defined. Some institutions require monitoring of baseline and postinfusion heart rate and blood pressure when a patient's response to beta-blockade has not been characterized (ie, the patient's initial dose or following a change in dose). Consult individual institutional policies and procedures.</p></div>
<div class="block pha drugH1Div" id="F195755"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Selective inhibitor of beta<sub>1</sub>-adrenergic receptors; competitively blocks beta<sub>1</sub>-receptors, with little or no effect on beta<sub>2</sub>-receptors at oral doses &lt;100 mg (in adults); does not exhibit any membrane stabilizing or intrinsic sympathomimetic activity</p></div>
<div class="block phk drugH1Div" id="F195774"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The pharmacokinetics of metoprolol succinate ER capsule or tablet in hypertensive children and adolescents 6 to 17 years of age were found to be similar to adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: IR tablets: Within 1 hour; Peak effect: Oral: 1 to 2 hours (Regardh 1980); IV: ~20 minutes (when infused over 10 minutes).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Oral: Immediate release: Variable (dose-related; 50% reduction in maximum heart rate after single doses of 20, 50, and 100 mg occurred at 3.3, 5, and 6.4 hours, respectively); Extended release: ~24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 3.2 to 5.6 L/kg; crosses the blood brain barrier; CSF concentrations are 78% of plasma concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~10% to 12% to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via CYP2D6; significant first-pass effect (~50%).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Immediate release: ~40% to 50% (Johnsson 1975); Extended release: 77% relative to immediate release.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Neonates: 5 to 10 hours (Morselli 1989); Adults: 3 to 4 hours (7 to 9 hours in poor CYP2D6 metabolizers or hepatic impairment).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (95%, &lt;5% to 10% as unchanged drug; increased to 30% to 40% in poor CYP2D6 metabolizers).</p></div>
<div class="block phksp drugH1Div" id="F51159551"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Elimination half-life may be considerably prolonged, depending on severity.</p>
<p style="text-indent:-2em;margin-left:2em;">Pharmacogenomics: Poor CYP2D6 metabolizers have several-fold higher metoprolol plasma concentrations.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F195781"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo metoprolol | Betaloc | Cadmet xr | Lopresor | Seloken xl</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Belozok | Lopresor</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Beloc | Beloc duriles | Lanoc | Metohexal | Metomed | Metoprolol | Metoprolol actavis | Metoprolol genericon pharma | Metoprolol sandoz | Metoprolol stada | Metoprololtartrat Hexal | Metotens | Seloken</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo metoprolol | Betaloc | Cm metoprolol | Genrx metoprolol | Lopresor | Metatar | Metohexal | Metolol | Metoprolol | Metoprolol actavis | Metoprolol an | Metoprolol mylan | Metoprolol rbx | Metoprolol sandoz | Metrol | Minax | Mistrom | Noumed metoprolol | Topreloc xl | Toprol | Tw metoprolol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Angilat | Betacard | Betaloc | Betaone | Metaloc | Metocard | Metoprol xl | Preloc | Presonil | Prolol | Selomet | Topress</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lopresor | Metoprolol EG | Metoprolol Mylan | Metoprolol sandoz | Metoprolol teva | Metoprolol teva generics belgium | Seloken | Selozok</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Met xl</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Betablockade | Betaloc | Corvitol | Egilok | Lopresor | Mecorlong | Metocor | Metoprolol | Metoprolol tartrate accord | Metostad | Metostad cr | Promerol | Succiprol | Vasocardin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Beca | Betacris | Dozoito | Emprol xr | Inephoros xr | Lopressor | Miclox | Minola | Quenzor | Seloken | Selozok | Succinato de metoprolol | Tartarato de metoprolol | Zarmine</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Beloc | Lopresor | Meto Zerok | Metoprol zok mepha | Metoprolol Actavis Zerok | Metoprolol Axapharm | Metoprolol helvepharm | Metoprolol spirig hc | Metoprolol teva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Met xl | Revelol-xl</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Lopresor | Meprokem</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Heng de | Metoprolol | Shu meng | Yi jie er</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Beloc | Betaloc | Betaloc zok | Betoprolol | Carprol ls | Etoprol | Grandil | Lopresor | Metoprolol | Metoprolol mk | Metoprolol tartrato | Metpure xl | Presartin | Prezoc | Tensoprol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo metoprolol | Betaloc | Betaloc zok | Bloxazoc | Egilok | Egilok succ | Emzok | Metoprolol | Metoprolol al | Metoprolol aurovitas | Metoprolol dh | Metoprolol medreg | Metoprolol Mylan | Vasocardin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Agoloc | Azumetop | Beloc | Beloc duriles | Beloc zok | Beloc zok mite | Dignometoprol | Jeprolol | Jutabloc | Lopresor | Lopressor | Meprolol | Metizok | Meto | Meto biochemie | Meto Hennig | Meto isis | Meto phamos | Meto tablinen | Meto-isis NT | Meto-Puren | Metoberag | Metobeta | Metodoc | Metodura | Metodura znt | Metohexal | Metohexal Succ | Metok | Metomerck | Metoprogamma | Metoprogamma succinat | Metoprolol | Metoprolol - 1 a pharma | Metoprolol 1 A Pharma Succ | Metoprolol abz | Metoprolol actavis | Metoprolol al | Metoprolol axcount | Metoprolol bioeq pharma | Metoprolol carino | Metoprolol carinopharm | Metoprolol Corax | Metoprolol CT | Metoprolol ct zero | Metoprolol Gry | Metoprolol Heumann | Metoprolol Heumann Heunet | Metoprolol ratiopharm Succinat | Metoprolol sandoz | Metoprolol stada | Metoprolol Succ CT | Metoprolol succinat acino | Metoprolol succinat actavis | Metoprolol succinat Beta | Metoprolol Succinat tad | Metoprolol Verla | Metoprolol von ct | Metoprolol wolff | Metoprolol z al | Metoprolol ZOT stada | Metoprolol-ratiopharm | Metoprololsuccinat 1 A Pharma | Metoprololsuccinat aaa | Metoprololsuccinat AbZ | Metoprololsuccinat AL | Metoprololsuccinat bioeq pharma | Metoprololsuccinat dura | Metoprololsuccinat heumann | Metoprololsuccinat STADA | Metoprolsuccinat amneal | Metoprolsuccinate Teva | Metoprolsuccinate Winthrop | Metowieb | Prelis | Selokeen | Seloken | Selozok | Sigaprolol</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Metocar | Metoprolol GEA | Metoprololsuccinat 1a farma | Metoprololsuccinat hexal | Metoratio</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Betaloc zok | Cardeler | Lopresor | Meprolol | Metopres | Metoprolol | Metoprolol lam | Prolaken | Ritmol | Tadilor | Vidacor</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Betaloc zok | Metoprolol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Betaloc zok | Bloxazoc | Corvitol | Emzok | Lopresor | Metohexal | Metoprolol | Metoprolol Polpharma | Metoprolol ratiopharm | Metoprolol stada | Metoprolol-ratiopharm | Metozok | Spesicor | Spesimax | Vasocardin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Carditag xl | Lopresor | Lowpress</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Beloken | Lopresor | Metoprolol aurovitas | Metoprolol krka</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Betaloc zok | Melopres | Metoprolol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Metblock | Metohexal | Metomylan | Metopocor | Metoprolin | Metoprolol krka | Metoprolol orion | Metoprolol ratiopharm | Metoprolol tartrate hexal | Seloken | Seloken zoc | Selopral | Spesicor | Spesimax</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lopressor | Metoprolol accord | Metoprolol actavis | Metoprolol arrow | Metoprolol g gam | Metoprolol Ranbaxy | Metoprolol rpg | Metoprolol sandoz | Seloken | Selozok | Selozok LP</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Arbralene | Betaloc | Lopresor | Mepranix | Metoprolol | Metoprolol berk | Metoprolol cox | Metoprolol kent | Metoprolol sandoz | Tensomex | Toprol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Beloc | Lopresor | Metazero</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo metoprolol | Betaloc | Betaloc zok | Metolol cp | Metoprolol | Metoprolol krka | Metracin | Minax | Slow metoprolol | Syn-Metoprolol</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Betaloc zok | Bloxan</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Egilok | Huma-metoprol | Metohexal | Metoprolol al | Metoprolol-b | Metoprolol-ratiopharm | Ritmetol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Betaloc zok | Cardiosel | Fapresor | Lopressor | Loprolol | Seloken | Selozok</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Betazok | Lopresor | Metocor | Metop</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lopresor | Metopress | Neobloc</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acmeto xl | Aimet xr | Almetolol | Angibloc ER | Arelol 25 sr | Beboxia 25 xl | Beboxia 50 xl | Belol | Best beta | Betabest | Betafit | Betaloc | Betaone | Betaone xl | Blumeta | Cardibeta | Cymet | Dilnorm | Embeta | Emlol | Evimeto | Ibmeto xr | Lakmet | Libmet xl | Lopresor | Mataprol | Megapralol xl | Meptolol | Met xl | Metacure | Metaloc | Metapro | Metapro-XL | Metcy | Metfine xl | Metfirst xl | Meto | Metoan er | Metocard xl | Metoder XL | Metograf | Metogud xl | Metolar | Metolar XR | Metonce | Metopil | Metopot | Metoprol xl | Metosan xr | Metox | Metozaar | Metozox | Metprocer xl | Metproleap | Metpure | Metpure xl | Metscore | Metspot | Metsun xl | Metvio cr | Metvolen xl | Metzok | Mexcelol | Mexmet | Mpl | Mprol | Mt loc | Myoprol XL | Naypres xl | Normomet xl | Numet | Oldbeta xl | Ozolol xl | Prolomet xl | Prolovas xl | Protol | Restopress | Revelol | Revelol-xl | Seloken | Sitelol | Sms-XL | Starpress XL | Supermet xl | Sustamet | Sustameto | Tamepro | Tecbeta | Translol xl | Trulol | Velol xl | Vinicor-XL | Vitameto xr | Vivalol | Voizmet | Xm Beta | Zenmet xl</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Meto rx | Metoprolol awa | Metorx</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lopresor | Metoprololo | Metoprololo aristo | Metoprololo aurobindo | Metoprololo Doc | Metoprololo eg | Metoprololo hexal | Metoprololo krka | Seloken</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Lopresor</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cerekunart | Hanilost | Kalsuhon | Kokonalin | Lopresor | Medepine | Melucomon | Metolastar | Metoplic | Metoplic taiyo | Mitacard | Selekton | Selekton choseido | Seloken | Seloken l | Shinzanol amel | Sioptorol | Sipseron | Zegmular | Zizel</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Betaloc zok | Lopressor | Met xl | Metpure xl | Revelol-xl</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Prolol</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Lopresor</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Betablok sdk | Betaloc zok | Lopresor</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo metoprolol | Betaloc | Bloxan | Corvitol | Emzok | Lopressor | Metazero | Meto isis | Meto-Puren | Metocard | Metohexal | Metohexal Succ | Metoprolol | Metoprolol Polpharma | Metoprolong | Spesicor | Vasocardin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Lopresor | Metohexal | Metohexal Succ | Metoprolol EG | Prelis | Seloken | Selozok</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Apo metoprolol | Betaloc | Betaloc zok | Bloxan | Corvitol | Egilok | Emzok | Lopresor | Metazero | Meto | Metohexal | Metoprogamma | Metoprolol | Metoprolol hexal z | Metoprolol Meda | Metoprolol Polpharma | Metoprolol ratiopharm | Spesicor | Vasocardin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Lopressor</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Apoprole | Begamar | Betaloc zok | Bioprol | Delandex | Eurolol | Futaline | Kapirmetol | Kenaprol | Laera | Lenopres | Lopresor | Lopresor r | Lopritol | Metobest | Metopresol | Metoprolol | Metoprolol avivia | Metoprolol g.i | Metoprolol jayor | Metoprolol kener | Metoprolol tecnofarma | Metoprolol victory | Mezelol | Nipresol | Ovaxtyl | Proken-m | Prolaken | Promiced | Prontol | Ritmolol | Ruteral | Seloken | Seloken Zok | Sermetrol | Synadrenol | Tiazidol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Aft metoprolol cr | Apo metoprolol | Beatrolol | Betaloc | Betatab | Betawin | Denex | Hypersor | Metohexal | Metoprolol | Metoprolol Pharmaniaga</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Betaloc zok | Met xl | Metoloc xl | Metpure xl</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lopresor | Metoprolol | Metoprololsuccinaat 1A pharma retard | Metoprololsuccinaat ratiopharm | Metoprololsuccinaat sandoz | Metoprololtartraat Accord | Metoprololtartraat actavis | Metoprololtartraat Alpharma | Metoprololtartraat aurobindo | Metoprololtartraat CF | Metoprololtartraat flx | Metoprololtartraat Mylan | Metoprololtartraat pch | Metoprololtartraat ratiopharm | Metoprololtartraat Sandoz | Metorpololtartraat A | Selokeen | Selokeen zoc | Seloken | Selozok</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Betaloc zok | Bloxazoc | Metopocor | Metoprolol | Metoprolol 50 1a pharma | Metoprolol actavis | Metoprolol al 50 nordic prime | Metoprolol mylan | Metoprolol retard gea | Metoprolol retard sandoz | Metoprolol sandoz | Metoprolol teva | Metoprololtartrat nordic prime | Selo zok | Seloken</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo metoprolol | Betaloc | Lopresor | Metoprolol mylan</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Betaloc zok | Revelol-xl</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Angimet | Angiobloc | Angionorm | Betaloc | Betaryx | Betazok | Boie Metoprolol Tartrate | Cardiopin | Cardiosel | Cardiostat | Corbloc | Embeta xr | Gerbloc | Hypetor | Metobloc | Metocard | Metocare | Metoprim | Metoprolol | Metoprolol Interhealth Care | Metospec | Metostad | Montebloc | Neobloc | Neox | Neox ER | Princicar | Prolat | Prolohex | Prolol | Prometin | Recebloc | Sanerg | Valvexin | Zionel</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aksopresor | Betaloc | Carsel | Liskoprol | Lopresor | Mepresor | Meprol | Merol | Metapressor | Metocard | Metopro | Metsim | Refit</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Beloc | Betaloc | Betaloc zok | Beto 50 zk | Beto zk | Bloxazoc | Iviprolol | Metocard | Metocard zk | Metogen sc | Metohexal | Metoprolol | Metoprolol 1A Pharma | Metoprolol biofarm | Metoprololum 123ratio | Metoratio Zk | Metostad | Selmet | Seloken | Symlok</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Kapspargo sprinkle | Lopressor | Metoprolol | Toprol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lopresor | Metoprolol | Metoprolol Aurobindo</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Lopresor | Metpure xl</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lopresor | Lopresor SR</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Betaloc zok | Betaprol | Bloxan | Egilok | Egilok ep | Emzok | Metoprolol medreg | Metoprolol zentiva | Metosuccinat | Vasocardin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Betaloc zok | Betalok | Corvitol | Egilok | Emzok | Metocard | Metocor | Metolol | Metoprolol | Metoprolol acry | Metoprolol akri | Metoprolol Akrikhin | Metoprolol krka | Metoprolol Obolensk | Metoprolol organika | Metoprolol retard akrikhin | Metoprolol teva | Metoprolol velfarm | Metoprolol vertex | Metoprolol zentiva | Metoprolol-ratiopharm | Metozok | Serdol | Vasocardin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo metoprolol | Carelio | Lopresor | Metracin | Pms-metoprolol | Pms-metoprolol-l</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bloxazoc | Metomylan | Metoproferm | Metoprolol 1A Farma Retard | Metoprolol actavis | Metoprolol biochemie | Metoprolol ebb | Metoprolol GEA | Metoprolol Hexal | Metoprolol ipex | Metoprolol Orifarm | Metoprolol orion | Metoprolol ratiopharm | Metoprolol sandoz | Mozoc | Seloken | SelokenZoc</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Denex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Beloc | Bloxan | Metoprolol carinopharm | Seloken</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Corvitol | Egilok | Egilok xl | Metoprolol medreg | Metoprolol Mylan | Metoprolol ratiopharm | Vasocardin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Betaloc zok | Cardeloc | Cardoxone r | Denex | Hyperloc | Lopresor | Meloc | Melol | Metoblock | Metocard | Metoloc | Metolol | Metoprolol | Metprolol | Minax | Sefloc</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Lopressor | Lopressor LP | Vasocard LP | Vasocardin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Beloc | Betablok sdk | Cardovol | Lopresor | Mepolex | Metloc | Probloc | Problok | Saneloc</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo metoprolol | Betaloc | Betapress | Betterlock | Cancliol | Cartaloc | Denex</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Corvitol | Egiloc | Egilok retard | Emzok | Metoprol retard | Metoprolol | Metoprolol Tartras | Metoprolol xl | Metoprolol zentiva | Vasocardin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Betaloc zok | Met xl | Metomac | Metpure xl</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Belozok | Lopresor | Mebuten | Zion</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Betaloc | Lopresor | Metoprolol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Lopresor</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Metpure xl | Revelol-xl</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Betaloc zok | Revelol-xl</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-17499863">
<a name="17499863"></a>Acikel S, Bozbas H, Gultekin B, et al. Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. <i>Int J Cardiol</i>. 2008;126(1):108-113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/17499863/pubmed" id="17499863" target="_blank">17499863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21112460">
<a name="21112460"></a>Ahmed AI, van Mierlo P, Jansen P. Sleep disorders, nightmares, depression and anxiety in an elderly patient treated with low-dose metoprolol. <i>Gen Hosp Psychiatry</i>. 2010;32(6). doi:10.1016/j.genhosppsych.2010.04.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/21112460/pubmed" id="21112460" target="_blank">21112460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: Update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084731">
<a name="29084731"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published online October 30, 2017]. <i>Circulation</i>. doi:10.1161/CIR.0000000000000549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/29084731/pubmed" id="29084731" target="_blank">29084731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. <i>Pediatrics</i>. 2011;128(suppl 5):S213-S256.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1089/bfm.2017.0077<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Circulation.</i> 2011;123(21):2434-2506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21700562">
<a name="21700562"></a>Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. <i>Endocr Pract</i>. 2011;17(3):456-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/21700562/pubmed" id="21700562" target="_blank">21700562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23796325">
<a name="23796325"></a>Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. <i>Int J Cardiol</i>. 2013;168(4):3572-3579. doi:10.1016/j.ijcard.2013.05.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/23796325/pubmed" id="23796325" target="_blank">23796325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17236889">
<a name="17236889"></a>Batisky DL, Sorof JM, Sugg J, et al. Efficacy and Safety of Extended Release Metoprolol Succinate in Hypertensive Children 6 to 16 Years of Age: A Clinical Trial Experience. <i>J Pediatr</i>. 2007;150(2):134-139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/17236889/pubmed" id="17236889" target="_blank">17236889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24607033">
<a name="24607033"></a>Bratt EL, Östman-Smith I. Effects of lifestyle changes and high-dose β-blocker therapy on exercise capacity in children, adolescents, and young adults with hypertrophic cardiomyopathy. <i>Cardiol Young</i>. 2015;25(3):501-510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/24607033/pubmed" id="24607033" target="_blank">24607033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29746858">
<a name="29746858"></a>Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. <i>J Urol</i>. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/29746858/pubmed" id="29746858" target="_blank">29746858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26715033">
<a name="26715033"></a>Burkauskas J, Noreikaite A, Bunevicius A, et al. Beta-1-selective beta-blockers and cognitive functions in patients with coronary artery disease: a cross-sectional study. <i>J Neuropsychiatry Clin Neurosci</i>. 2016;28(2):143-146. doi:10.1176/appi.neuropsych.15040088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/26715033/pubmed" id="26715033" target="_blank">26715033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29699616">
<a name="29699616"></a>Chatzidou S, Kontogiannis C, Tsilimigras DI, et al. Propranolol versus metoprolol for treatment of electrical storm in patients with implantable cardioverter-defibrillator. <i>J Am Coll Cardiol.</i> 2018;71(17):1897-1906. doi:10.1016/j.jacc.2018.02.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/29699616/pubmed" id="29699616" target="_blank">29699616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chaudhary.1">
<a name="Chaudhary.1"></a>Chaudhary I. Microvascular angina: angina pectoris with normal coronary arteries. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16271643">
<a name="16271643"></a>Chen ZM, Pan HC, Chen YP, et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. <i>Lancet</i>. 2005;366(9497):1622-1632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/16271643/pubmed" id="16271643" target="_blank">16271643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18654082">
<a name="18654082"></a>Cocco G. Erectile dysfunction after therapy with metoprolol: the Hawthorne effect. <i>Cardiology</i>. 2009;112(3):174-177. doi:10.1159/000147951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/18654082/pubmed" id="18654082" target="_blank">18654082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15579370">
<a name="15579370"></a>Covar RA, Macomber BA, Szefler SJ. Medications as asthma triggers. <i>Immunol Allergy Clin North Am</i>. 2005;25(1):169-190. doi:10.1016/j.iac.2004.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/15579370/pubmed" id="15579370" target="_blank">15579370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4054193">
<a name="4054193"></a>Cove-Smith JR, Kirk CA. CNS-related side-effects with metoprolol and atenolol. Eur J Clin Pharmacol. 1985;(28)(suppl):69-72. doi:10.1007/BF00543713<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/4054193/pubmed" id="4054193" target="_blank">4054193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3009050">
<a name="3009050"></a>Croft CH, Rude RE, Gustafson N, et al. Abrupt withdrawal of beta-blockade therapy in patients with myocardial infarction: effects on infarct size, left ventricular function, and hospital course. <i>Circulation</i>. 1986;73(6):1281-1290. doi:10.1161/01.cir.73.6.1281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/3009050/pubmed" id="3009050" target="_blank">3009050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969714">
<a name="1969714"></a>Dahlöf C, Dimenäs E. Side effects of beta-blocker treatments as related to the central nervous system. <i>Am J Med Sci</i>. 1990;299(4):236-244. doi:10.1097/00000441-199004000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/1969714/pubmed" id="1969714" target="_blank">1969714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6122483">
<a name="6122483"></a>Day JL, Metcalfe J, Simpson CN. Adrenergic mechanisms in control of plasma lipid concentrations. <i>Br Med J (Clin Res Ed)</i>. 1982;284(6323):1145-1148. doi:10.1136/bmj.284.6323.1145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/6122483/pubmed" id="6122483" target="_blank">6122483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11422094">
<a name="11422094"></a>Diener HC, Hartung E, Chrubasik J, et al; Study Group. A comparative study of oral acetylsalicylic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study. <i>Cephalalgia</i>. 2001;21(2):120-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/11422094/pubmed" id="11422094" target="_blank">11422094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27761769">
<a name="27761769"></a>Doyon JB, Liu KJ, Berman RA. Metoprolol-induced total body erythroderma. <i>J Gen Intern Med</i>. 2017;32(2):221-222. doi:10.1007/s11606-016-3900-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/27761769/pubmed" id="27761769" target="_blank">27761769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31633896">
<a name="31633896"></a>Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the Prevention of Acute Exacerbations of COPD. <i>N Engl J Med</i>. 2019;381(24):2304-2314. doi:10.1056/NEJMoa1908142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/31633896/pubmed" id="31633896" target="_blank">31633896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2891122">
<a name="2891122"></a>Drayer DE. Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers. <i>Pharmacotherapy</i>. 1987;7(4):87-91. doi:10.1002/j.1875-9114.1987.tb04029.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/2891122/pubmed" id="2891122" target="_blank">2891122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31775749">
<a name="31775749"></a>Dungan K, Merrill J, Long C, Binkley P. Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients. <i>Cardiovasc Diabetol</i>. 2019;18(1):163. Published 2019 Nov 27. doi:10.1186/s12933-019-0967-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/31775749/pubmed" id="31775749" target="_blank">31775749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10376614">
<a name="10376614"></a>Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). <i>Lancet</i>. 1999;353(9169):2001-2007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/10376614/pubmed" id="10376614" target="_blank">10376614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2897781">
<a name="2897781"></a>Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. <i>Am J Cardiol</i>. 1988;61(15):1219-1222. doi:10.1016/0002-9149(88)91158-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/2897781/pubmed" id="2897781" target="_blank">2897781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33945044">
<a name="33945044"></a>Farmakis IT, Pyrgidis N, Doundoulakis I, Mykoniatis I, Akrivos E, Giannakoulas G. Effects of major antihypertensive drug classes on erectile function: a network meta-analysis. <i>Cardiovasc Drugs Ther</i>. Published online May 4, 2021. doi:10.1007/s10557-021-07197-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/33945044/pubmed" id="33945044" target="_blank">33945044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):640-656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons [published correction appears in <i>Circulation</i>. 2014;129(16):e463]. <i>Circulation</i>. 2012;126(25):e354-e471. doi:10.1161/CIR.0b013e318277d6a0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12090909">
<a name="12090909"></a>Fisher AA, Davis M, Jeffery I. Acute delirium induced by metoprolol. <i>Cardiovasc Drugs Ther</i>. 2002;16(2):161-165. doi:10.1023/a:1015761618314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/12090909/pubmed" id="12090909" target="_blank">12090909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29192011">
<a name="29192011"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3):e20171904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/29192011/pubmed" id="29192011" target="_blank">29192011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18617067">
<a name="18617067"></a>Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. <i>J Am Coll Cardiol</i>. 2008;52(3):190-199. doi:10.1016/j.jacc.2008.03.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/18617067/pubmed" id="18617067" target="_blank">18617067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20067434">
<a name="20067434"></a>Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. <i>Curr Med Res Opin</i>. 2010;26(3):615-629. doi:10.1185/03007990903533681<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/20067434/pubmed" id="20067434" target="_blank">20067434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6867180">
<a name="6867180"></a>Foster CA, Aston SJ. Propranolol-Epinephrine Interaction: A Potential Disaster. <i>Plast Reconstr Surg</i>. 1983;72(1):74-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/6867180/pubmed" id="6867180" target="_blank">6867180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2895072">
<a name="2895072"></a>Frishman WH. Beta-adrenergic receptor blockers. Adverse effects and drug interactions. <i>Hypertension</i>. 1988;11(3, pt 2):II21-II29. doi:10.1161/01.hyp.11.3_pt_2.ii21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/2895072/pubmed" id="2895072" target="_blank">2895072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2883874">
<a name="2883874"></a>Frishman WH. Beta-adrenergic blocker withdrawal. <i>Am J Cardiol</i>. 1987;59(13):26F-32F. doi:10.1016/0002-9149(87)90038-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/2883874/pubmed" id="2883874" target="_blank">2883874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8956349">
<a name="8956349"></a>Gleiter CH, Deckert J. Adverse CNS-effects of beta-adrenoceptor blockers. <i>Pharmacopsychiatry</i>. 1996;29(6):201-211. doi:10.1055/s-2007-979572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/8956349/pubmed" id="8956349" target="_blank">8956349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grundmann.1">
<a name="Grundmann.1"></a>Grundmann M, Kacirova I, Duricova, J et al. "Metoprolol and alfa-hydroxymetoprolol concentrations during lactation-a case report.” 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology Stuttgart, Germany · October 2 – 6, 2011. <i>Ther Drug Monit</i>. 2011;33(4):504.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17765616">
<a name="17765616"></a>Haghjoo M, Saravi M, Hashemi MJ, et al. Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. <i>Heart Rhythm</i>. 2007;4(9):1170-1174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/17765616/pubmed" id="17765616" target="_blank">17765616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29260695">
<a name="29260695"></a>Hansen T, Fynne L. Jaundice and liver injury with cholestatic pattern after treatment with metoprololsuccinat [in Danish]. <i>Ugeskr Laeger</i>. 2017;179(51):V09170698.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/29260695/pubmed" id="29260695" target="_blank">29260695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1244260">
<a name="1244260"></a>Harrison DC, Alderman EL. Editorial: Discontinuation of propranolol therapy. Cause of rebound angina pectoris and acute coronary events. <i>Chest</i>. 1976;69(1):1-2. doi:10.1378/chest.69.1.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/1244260/pubmed" id="1244260" target="_blank">1244260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation.</i> 2011;124(23):2610-2642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16549646">
<a name="16549646"></a>Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary. A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). <i>Circulation.</i> 2006;113(11):1474-1547.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/16549646/pubmed" id="16549646" target="_blank">16549646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10372206">
<a name="10372206"></a>Ho TK, Moretti ME, Schaeffer JK et al. Maternal beta-blocker usage and breast feeding in the neonate. The American Pediatric Society and The Society for Pediatric Research 1999 annual meeting. San Francisco, California, USA. May 1-4, 1999. Abstracts. <i>Pediatr Res</i>. 1999;45(4, pt 2):67A.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/10372206/pubmed" id="10372206" target="_blank">10372206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7363533">
<a name="7363533"></a>Hoffmann KJ, Regårdh CG, Aurell M, Ervik M, Jordö L. The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites. <i>Clin Pharmacokinet</i>. 1980;5(2):181-191. doi:10.2165/00003088-198005020-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/7363533/pubmed" id="7363533" target="_blank">7363533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12561664">
<a name="12561664"></a>Huckleberry Y, Thomas MC, Erstad BL. Dosage conversions as a potential cause of adverse drug events. <i>Am J Health Syst Pharm</i>. 2003;60(2):189-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/12561664/pubmed" id="12561664" target="_blank">12561664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1977302">
<a name="1977302"></a>Jaillon P. Relevance of intrinsic sympathomimetic activity for beta blockers. <i>Am J Cardiol</i>. 1990;66(9):21C-23C. doi:10.1016/0002-9149(90)90758-s<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/1977302/pubmed" id="1977302" target="_blank">1977302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24685669">
<a name="24685669"></a>January CT, Wann LS, Alpert JS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/24685669/pubmed" id="24685669" target="_blank">24685669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30703530">
<a name="30703530"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>. 2019:S1547-5271(19)30037-2. doi:10.1016/j.hrthm.2019.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/30703530/pubmed" id="30703530" target="_blank">30703530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1094802">
<a name="1094802"></a>Johnsson G, Regårdh CG, Sölvell L. Combined pharmacokinetic and pharmacodynamic studies in man of the adrenergic beta1-receptor antagonist metoprolol. <i>Acta Pharmacol Toxicol (Copenh)</i>. 1975;36(suppl 5):31-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/1094802/pubmed" id="1094802" target="_blank">1094802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6102500">
<a name="6102500"></a>Jordö L, Attman PO, Aurell M, Johansson L, Johnsson G, Regårdh CG. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. <i>Clin Pharmacokinet</i>. 1980;5(2):169-180. doi:10.2165/00003088-198005020-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/6102500/pubmed" id="6102500" target="_blank">6102500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kannam.2019">
<a name="Kannam.2019"></a>Kannam JP, Gersh BJ. Beta blockers in the management of chronic coronary syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kapspargo.1">
<a name="Kapspargo.1"></a>Kapspargo (metoprolol) [prescribing information]. Cranbury, NJ: Sun Pharmaceuticals; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kapspargo.2">
<a name="Kapspargo.2"></a>Kapspargo Sprinkle (metoprolol) [prescribing information]. New Brunswick, NJ: Ohm Laboratories Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12494613">
<a name="12494613"></a>Kettering K, Mewis C, Dörnberger V, Vonthein R, Bosch RF, Kühlkamp V. Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. <i>Pacing Clin Electrophysiol</i>. 2002;25(11):1571-1576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/12494613/pubmed" id="12494613" target="_blank">12494613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25499948">
<a name="25499948"></a>Kim Y, Miller M. Marked hypertriglyceridemia in a woman receiving metoprolol succinate. <i>J Clin Lipidol</i>. 2014;8(6):640-643. doi:10.1016/j.jacl.2014.07.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/25499948/pubmed" id="25499948" target="_blank">25499948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6376011">
<a name="6376011"></a>Kleinbaum J, Shamoon H. Effect of propranolol on delayed glucose recovery after insulin-induced hypoglycemia in normal and diabetic subjects. <i>Diabetes Care</i>. 1984;7(2):155-162. doi:10.2337/diacare.7.2.155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/6376011/pubmed" id="6376011" target="_blank">6376011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Saunders Elsevier; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12117400">
<a name="12117400"></a>Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. <i>JAMA</i>. 2002;288(3):351-357. doi:10.1001/jama.288.3.351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/12117400/pubmed" id="12117400" target="_blank">12117400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2865151">
<a name="2865151"></a>Koella WP. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. <i>Eur J Clin Pharmacol</i>. 1985;28 Suppl:55-63. doi:10.1007/BF00543711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/2865151/pubmed" id="2865151" target="_blank">2865151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2878741">
<a name="2878741"></a>Kostis JB, Rosen RC. Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties. <i>Circulation</i>. 1987;75(1):204-212. doi:10.1161/01.cir.75.1.204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/2878741/pubmed" id="2878741" target="_blank">2878741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12490274">
<a name="12490274"></a>Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. <i>J Heart Lung Transplant</i>. 2002;21(12):1290-1295. doi:10.1016/s1053-2498(02)00459-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/12490274/pubmed" id="12490274" target="_blank">12490274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10942742">
<a name="10942742"></a>Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). <i>Circulation</i>. 2000;102(7):748-754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/10942742/pubmed" id="10942742" target="_blank">10942742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30412710">
<a name="30412710"></a>Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2019;74(7):932-987. doi:10.1016/j.jacc.2018.10.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/30412710/pubmed" id="30412710" target="_blank">30412710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-85053">
<a name="85053"></a>Lager I, Blohmé G, Smith U. Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. <i>Lancet</i>. 1979;1(8114):458-462. doi:10.1016/s0140-6736(79)90821-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/85053/pubmed" id="85053" target="_blank">85053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2439802">
<a name="2439802"></a>Lammers JW, Folgering HT, van Herwaarden CL. Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. <i>J Cardiovasc Pharmacol</i>. 1986;8 Suppl 11:S69-S73. doi:10.1097/00005344-198511001-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/2439802/pubmed" id="2439802" target="_blank">2439802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3337519">
<a name="3337519"></a>Larrey D, Henrion J, Heller F, et al. Metoprolol-induced hepatitis: rechallenge and drug oxidation phenotyping. <i>Ann Intern Med</i>. 1988;108(1):67-68. doi:10.7326/0003-4819-108-1-67<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/3337519/pubmed" id="3337519" target="_blank">3337519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37093">
<a name="37093"></a>Lederballe Pedersen O, Mikkelsen E, Lanng Nielsen J, Christensen NJ. Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin. <i>Eur J Clin Pharmacol</i>. 1979;15(3):215-217. doi:10.1007/BF00563108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/37093/pubmed" id="37093" target="_blank">37093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lee.1">
<a name="Lee.1"></a>Lee R. Atrial fibrillation and flutter after cardiac surgery. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22267844">
<a name="22267844"></a>Levine GN, Steinke EE, Bakaeen FG, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Quality of Care and Outcomes Research. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2012;125(8):1058-1072. doi:10.1161/CIR.0b013e3182447787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/22267844/pubmed" id="22267844" target="_blank">22267844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7286041">
<a name="7286041"></a>Liedholm H, Melander A, Bitzén PO, et al. Accumulation of Atenolol and Metoprolol in Human Breast Milk. <i>Eur J Clin Pharmacol</i>. 1981;20(3):229-231.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/7286041/pubmed" id="7286041" target="_blank">7286041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3443141">
<a name="3443141"></a>Lindeberg S, Lundborg P, Regårdh CG, et al. Disposition of the Adrenergic Blocker Metoprolol and its Metabolite OH-Metoprolol in Maternal Plasma, Amniotic Fluid and Capillary Blood of the Neonate. <i>Eur J Clin Pharmacol</i>. 1987;33(4):363-368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/3443141/pubmed" id="3443141" target="_blank">3443141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27390282">
<a name="27390282"></a>Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. <i>Eur Respir J</i>. 2016;48(3):880-888. doi:10.1183/13993003.01847-2015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/27390282/pubmed" id="27390282" target="_blank">27390282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28182127">
<a name="28182127"></a>Liu X, Lou X, Cheng X, Meng Y. Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders. <i>Drug Des Devel Ther</i>. 2017;11:305-312. doi:10.2147/DDDT.S124497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/28182127/pubmed" id="28182127" target="_blank">28182127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15288162">
<a name="15288162"></a>López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. <i>Eur Heart J</i>. 2004;25(15):1341-1362. doi:10.1016/j.ehj.2004.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/15288162/pubmed" id="15288162" target="_blank">15288162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lopressor.1">
<a name="Lopressor.1"></a>Lopressor (metoprolol tartrate, USP) tablets [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lopressor.2">
<a name="Lopressor.2"></a>Lopressor (metoprolol) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lopressor.3">
<a name="Lopressor.3"></a>Lopressor SR (metoprolol) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27899939">
<a name="27899939"></a>Lu HT, Kam J, Nordin RB, et al. Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. <i>J Geriatr Cardiol</i>. 2016;13(9):749-759. doi:10.11909/j.issn.1671-5411.2016.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/27899939/pubmed" id="27899939" target="_blank">27899939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline No. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9562933">
<a name="9562933"></a>Mayer S, Hillis LD. Prinzmetal's variant angina. <i>Clin Cardiol</i>. 1998;21(4):243-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/9562933/pubmed" id="9562933" target="_blank">9562933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969642">
<a name="1969642"></a>McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. <i>Pharmacol Ther</i>. 1990;46(2):163-197. doi:10.1016/0163-7258(90)90092-g<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/1969642/pubmed" id="1969642" target="_blank">1969642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-872491">
<a name="872491"></a>Melander A, Danielson K, Scherstén B, Wåhlin E. Enhancement of the bioavailability of propranolol and metoprolol by food. <i>Clin Pharmacol Ther</i>. 1977;22(1):108-112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/872491/pubmed" id="872491" target="_blank">872491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Juno.1">
<a name="Juno.1"></a>Metoprolol tartrate injection USP [product monograph]. Mississauga, Ontario, Canada: Juno Pharmaceuticals Corp; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Civica.1">
<a name="Civica.1"></a>Metoprolol tartrate injection ampuls [prescribing information]. Lehi, UT: Civica Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Civica.2">
<a name="Civica.2"></a>Metoprolol tartrate injection vials [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Metoprolol tartrate tablets [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; March 2015.</div>
</li>
<li>
<div class="reference">
                  Metoprolol tartrate tablets, USP [product monograph]. Brampton, Ontario, Canada: Sanis Health Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2861072">
<a name="2861072"></a>Mills GA, Horn JR. Beta-blockers and glucose control. <i>Drug Intell Clin Pharm</i>. 1985;19(4):246-251. doi:10.1177/106002808501900401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/2861072/pubmed" id="2861072" target="_blank">2861072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24202435">
<a name="24202435"></a>Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. <i>Chest</i>. 2014;145(4):779-786. doi:10.1378/chest.13-1235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/24202435/pubmed" id="24202435" target="_blank">24202435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28126029">
<a name="28126029"></a>Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. <i>BMC Med</i>. 2017;15(1):18. doi:10.1186/s12916-017-0781-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/28126029/pubmed" id="28126029" target="_blank">28126029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2693002">
<a name="2693002"></a>Morselli PL, Boutroy MJ, Bianchetti G, et al. Pharmacokinetics of Antihypertensive Drugs in the Neonatal Period. <i>Dev Pharmacol Ther</i>. 1989;13(2-4):190-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/2693002/pubmed" id="2693002" target="_blank">2693002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8438747">
<a name="8438747"></a>Muller G, Deal BJ, Strasburger JF, et al. Usefulness of Metoprolol for Unexplained Syncope and Positive Response to Tilt Testing in Young Persons. <i>Am J Cardiol</i>. 1993;71(7):592-595.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/8438747/pubmed" id="8438747" target="_blank">8438747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2004;114(suppl 2):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Clinical Practice Guidelines, 2011. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-436208">
<a name="436208"></a>Nattel S, Rangno RE, Van Loon G. Mechanism of propranolol withdrawal phenomena. <i>Circulation</i>. 1979;59(6):1158-1164. doi:10.1161/01.cir.59.6.1158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/436208/pubmed" id="436208" target="_blank">436208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [published corrections appear in <i>Circulation</i>. 2011;123(6):e236; <i>Circulation</i>. 2013;128(25):e480]. <i>Circulation</i>. 2010;122(18)(suppl 3):S729-S767. doi: 10.1161/CIRCULATIONAHA.110.970988.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21614631">
<a name="21614631"></a>Nguyen DL, Wittich CM. Metoprolol-induced lichenoid dermatitis. <i>J Gen Intern Med</i>. 2011;26(11):1379-1380. doi:10.1007/s11606-011-1742-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/21614631/pubmed" id="21614631" target="_blank">21614631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24155101">
<a name="24155101"></a>Nicolai MP, Liem SS, Both S, et al. A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. <i>Neth Heart J</i>. 2014;22(1):11-19. doi:10.1007/s12471-013-0482-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/24155101/pubmed" id="24155101" target="_blank">24155101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16967357">
<a name="16967357"></a>Nicpoń KW. Headache induced by oral intake of metoprolol in a patient with chronic and limited cardiac tamponade [in Polish]. <i>Neurol Neurochir Pol</i>. 2006;40(4):342-346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/16967357/pubmed" id="16967357" target="_blank">16967357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29766868">
<a name="29766868"></a>Nikolaidou T, Ghosh JM, Clark AL. Outcomes related to first-degree atrioventricular block and therapeutic implications in patients with heart failure. <i>JACC Clin Electrophysiol</i>. 2016;2(2):181-192. doi:10.1016/j.jacep.2016.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/29766868/pubmed" id="29766868" target="_blank">29766868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481]. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1533587">
<a name="1533587"></a>Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. <i>Eur Heart J.</i> 1992;13(1):28-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/1533587/pubmed" id="1533587" target="_blank">1533587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8121741">
<a name="8121741"></a>O'Marcaigh AS, MacLellan-Tobert SG, Porter CJ. Tilt-Table Testing and Oral Metoprolol Therapy in Young Patients With Unexplained Syncope. <i>Pediatrics</i>. 1994;93(2):278-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/8121741/pubmed" id="8121741" target="_blank">8121741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33229116">
<a name="33229116"></a>Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/33229116/pubmed" id="33229116" target="_blank">33229116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530749">
<a name="22530749"></a>Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular block. <i>Pacing Clin Electrophysiol</i>. 2012;35(7):804-810. doi:10.1111/j.1540-8159.2012.03410.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/22530749/pubmed" id="22530749" target="_blank">22530749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20727015">
<a name="20727015"></a>Ostman-Smith I. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death. <i>Fundam Clin Pharmacol</i>. 2010;24(5):637-652.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/20727015/pubmed" id="20727015" target="_blank">20727015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10577575">
<a name="10577575"></a>Ostman-Smith I, Wettrell G, Riesenfield T. A Cohort Study of Childhood Hypertrophic Cardiomyopathy: Improved Survival Following High-Dose Beta-Adrenoceptor Antagonist Treatment. <i>J Am Coll Cardiol</i>. 1999;34(6):1813-1822.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/10577575/pubmed" id="10577575" target="_blank">10577575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23232844">
<a name="23232844"></a>Ozaydin M, Icli A, Yucel H, et al. Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study. <i>Eur Heart J</i>. 2013;34(8):597-604. doi:10.1093/eurheartj/ehs423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/23232844/pubmed" id="23232844" target="_blank">23232844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26409259">
<a name="26409259"></a>Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in <i>J Am Coll Cardiol. </i>2016;68(25):2922-2923]. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/26409259/pubmed" id="26409259" target="_blank">26409259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park, MK. <i>Pediatric Cardiology for Practitioners</i>. 6th ed. Elsevier Health Sciences; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6344309">
<a name="6344309"></a>Patakas D, Argiropoulou V, Louridas G, Tsara V. Beta-blockers in bronchial asthma: effect of propranolol and pindolol on large and small airways. <i>Thorax</i>. 1983;38(2):108-112. doi:10.1136/thx.38.2.108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/6344309/pubmed" id="6344309" target="_blank">6344309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31490034">
<a name="31490034"></a>Patel S, Kim S, Allen C. Metoprolol-induced pemphigus-like reaction. <i>Clin Adv Periodontics</i>. 2019;9(1):24-28. doi:10.1002/cap.10044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/31490034/pubmed" id="31490034" target="_blank">31490034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16302561">
<a name="16302561"></a>Perry A, Sparling JD, Pennington M. Bullous pemphigoid following therapy with an oral beta-blocker. <i>J Drugs Dermatol</i>. 2005;4(6):746-748.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/16302561/pubmed" id="16302561" target="_blank">16302561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28589058">
<a name="28589058"></a>Philips C, Paramaguru R, Mahadevan P, Ravindranath J, Augustine P. Metoprolol-induced severe liver injury and successful management with therapeutic plasma exchange. <i>Cureus</i>. 2017;9(5):e1209. doi:10.7759/cureus.1209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/28589058/pubmed" id="28589058" target="_blank">28589058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6376017">
<a name="6376017"></a>Popp DA, Tse TF, Shah SD, Clutter WE, Cryer PE. Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus. <i>Diabetes Care</i>. 1984;7(3):243-247. doi:10.2337/diacare.7.3.243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/6376017/pubmed" id="6376017" target="_blank">6376017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22683887">
<a name="22683887"></a>Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. <i>Can J Neurol Sci</i>. 2012;39(2 Suppl 2):S1-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/22683887/pubmed" id="22683887" target="_blank">22683887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2897302">
<a name="2897302"></a>Proclemer A, Gradnik R, Savonitto S, Feruglio GA. Electrophysiological effects of bisoprolol. <i>Eur Heart J</i>. 1987;8(suppl M):81-85. doi:10.1093/eurheartj/8.suppl_m.81<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/2897302/pubmed" id="2897302" target="_blank">2897302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2450898">
<a name="2450898"></a>Prystowsky EN. The effects of slow channel blockers and beta blockers on atrioventricular nodal conduction. <i>J Clin Pharmacol</i>. 1988;28(1):6-21. doi:10.1002/j.1552-4604.1988.tb03095.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/2450898/pubmed" id="2450898" target="_blank">2450898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1968518">
<a name="1968518"></a>Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA. 1990;263(12):1653-1657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/1968518/pubmed" id="1968518" target="_blank">1968518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26995368">
<a name="26995368"></a>Ranchord AM, Spertus JA, Buchanan DM, Gosch KL, Chan PS. Initiation of β-blocker therapy and depression after acute myocardial infarction. <i>Am Heart J</i>. 2016;174:37-42. doi:10.1016/j.ahj.2015.11.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/26995368/pubmed" id="26995368" target="_blank">26995368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6125187">
<a name="6125187"></a>Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. <i>Br J Clin Pharmacol</i>. 1982;13(Suppl 2):345S-351S. doi:10.1111/j.1365-2125.1982.tb01939.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/6125187/pubmed" id="6125187" target="_blank">6125187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4155762">
<a name="4155762"></a>Regardh CG, Borg KO, Johansson R, Johnsson G, Palmer L. Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man. <i>J Pharmacokinet Biopharm</i>. 1974;2(4):347-364.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/4155762/pubmed" id="4155762" target="_blank">4155762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7002420">
<a name="7002420"></a>Regardh CG, Johnsson G. Clinical Pharmacokinetics of Metoprolol. <i>Clin Pharmacokinet</i>. 1980;5(6):557-569.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/7002420/pubmed" id="7002420" target="_blank">7002420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Riva.1">
<a name="Riva.1"></a>Riva-Metoprolol-L (metoprolol tartrate, USP) [product monograph]. Blainville, Quebec, Canada: Laboratoire Riva Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi:10.1016/j.jash.2015.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenson.1">
<a name="Rosenson.1"></a>Rosenson RS, Reeder GS, Kennedy HL. Acute myocardial infarction: role of beta blocker therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27521067">
<a name="27521067"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis [published correction appears in <i>Thyroid</i>. 2017;27(11):1462]. <i>Thyroid</i>. 2016;26(10):1343-1421. doi:10.1089/thy.2016.0229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/27521067/pubmed" id="27521067" target="_blank">27521067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6873132">
<a name="6873132"></a>Rössner S, Weiner L. Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects. <i>Eur J Clin Pharmacol</i>. 1983;24(5):573-577. doi:10.1007/BF00542203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/6873132/pubmed" id="6873132" target="_blank">6873132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26461463">
<a name="26461463"></a>Ryu RJ, Eyal S, Easterling TR, et al. Pharmacokinetics of metoprolol during pregnancy and lactation. <i>J Clin Pharmacol</i>. 2016;56(5):581-589.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/26461463/pubmed" id="26461463" target="_blank">26461463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12519582">
<a name="12519582"></a>Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. <i>Cochrane Database Syst Rev</i>. 2002;(4):CD002992. doi:10.1002/14651858.CD002992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/12519582/pubmed" id="12519582" target="_blank">12519582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6135523">
<a name="6135523"></a>Sandström B, Lindeberg S, Lundborg P, Regardh CG. Disposition of the adrenergic blocker metoprolol in the late pregnant women, the amniotic fluid, the cord blood and the neonate. <i>Clin Exp Hypertens B</i>. 1983;2(1):75-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/6135523/pubmed" id="6135523" target="_blank">6135523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23024438">
<a name="23024438"></a>Scheer FA, Morris CJ, Garcia JI, et al. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. <i>Sleep</i>. 2012;35(10):1395-1402. doi:10.5665/sleep.2122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/23024438/pubmed" id="23024438" target="_blank">23024438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18184294">
<a name="18184294"></a>Schellenberg R, Lichtenthal A, Wöhling H, Graf C, Brixius K. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment? <i>Headache</i>. 2008;48(1):118-125. doi: 10.1111/j.1526-4610.2007.00785.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/18184294/pubmed" id="18184294" target="_blank">18184294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.1">
<a name="Schwedt.1"></a>Schwedt TJ, Garza I. Preventive treatment of episodic migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9761084">
<a name="9761084"></a>Seidl K, Hauer B, Schwick NG, Zahn R, Senges J. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. <i>Am J Cardiol</i>. 1998;82(6):744-748.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/9761084/pubmed" id="9761084" target="_blank">9761084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7363534">
<a name="7363534"></a>Seiler KU, Schuster KJ, Meyer GJ, Niedermayer W, Wassermann O. The pharmacokinetics of metoprolol and its metabolites in dialysis patients. <i>Clin Pharmacokinet</i>. 1980;5(2):192-198. doi:10.2165/00003088-198005020-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/7363534/pubmed" id="7363534" target="_blank">7363534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28622464">
<a name="28622464"></a>Semet M, Paci M, Saïas-Magnan J, et al. The impact of drugs on male fertility: a review. <i>Andrology</i>. 2017;5(4):640-663. doi:10.1111/andr.12366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/28622464/pubmed" id="28622464" target="_blank">28622464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10328154">
<a name="10328154"></a>Shaddy RE, Tani LY, Gidding SS, et al. Beta-Blocker Treatment of Dilated Cardiomyopathy With Congestive Heart Failure in Children: A Multi-Institutional Experience. <i>J Heart Lung Transplant</i>. 1999;18(3):269-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/10328154/pubmed" id="10328154" target="_blank">10328154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-668066">
<a name="668066"></a>Shand DG, Wood AJ. Propranolol withdrawal syndrome - why?. <i>Circulation</i>. 1978;58(2):202-203. doi:10.1161/01.cir.58.2.202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/668066/pubmed" id="668066" target="_blank">668066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22529202">
<a name="22529202"></a>Silberstein SD, Holland S, Freitag F, et al; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society [published correction appears in <i>Neurology. </i>2013;80(9):871].<i> Neurology.</i> 2012;78(17):1337-1345.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/22529202/pubmed" id="22529202" target="_blank">22529202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14585251">
<a name="14585251"></a>Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. <i>Eur Heart J</i>. 2003;24(21):1928-1932. doi:10.1016/j.ehj.2003.08.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/14585251/pubmed" id="14585251" target="_blank">14585251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simons.1">
<a name="Simons.1"></a>Simons M, Breall JA. Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17116960">
<a name="17116960"></a>Sirois FJ. Visual hallucinations and metoprolol. <i>Psychosomatics</i>. 2006;47(6):537-538. doi:10.1176/appi.psy.47.6.537<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/17116960/pubmed" id="17116960" target="_blank">17116960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052934">
<a name="22052934"></a>Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation. <i>Circulation</i>. 2011;124(22):2458-2473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/22052934/pubmed" id="22052934" target="_blank">22052934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1983947">
<a name="1983947"></a>Snyder S. Metoprolol-induced polymyalgia-like syndrome. <i>Ann Intern Med</i>. 1991;114(1):96-97. doi:10.7326/0003-4819-114-1-96_2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/1983947/pubmed" id="1983947" target="_blank">1983947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113373">
<a name="31113373"></a>Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign against Headache. <i>J Headache Pain</i>. 2019;20(1):57. doi:10.1186/s10194-018-0899-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/31113373/pubmed" id="31113373" target="_blank">31113373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12708950">
<a name="12708950"></a>Tangeman HJ, Patterson JH. Extended-release metoprolol succinate in chronic heart failure. <i>Ann Pharmacother</i>. 2003;37(5):701-710.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/12708950/pubmed" id="12708950" target="_blank">12708950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28221167">
<a name="28221167"></a>Tatu AL, Nwabudike LC. Metoprolol-associated onset of psoriatic arthropathy. <i>Am J Ther</i>. 2017;24(3):e370-e371. doi:10.1097/MJT.0000000000000560<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/28221167/pubmed" id="28221167" target="_blank">28221167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34331033">
<a name="34331033"></a>Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. <i>Nat Rev Cardiol</i>. 2022;19(1):59-74. doi:10.1038/s41569-021-00593-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/34331033/pubmed" id="34331033" target="_blank">34331033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Toprol.1">
<a name="Toprol.1"></a>Toprol XL (metoprolol succinate) extended-release tablet [prescribing information]. Lincolnshire, IL: Melinta Therapeutics; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28559400">
<a name="28559400"></a>Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H. Risk of cardiovascular events in patients with diabetes mellitus on β-blockers. <i>Hypertension</i>. 2017;70(1):103-110. doi:10.1161/HYPERTENSIONAHA.117.09259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/28559400/pubmed" id="28559400" target="_blank">28559400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2257873">
<a name="2257873"></a>van den Berg G, van Steveninck F, Gubbens-Stibbe JM, Schoemaker HC, de Boer AG, Cohen AF. Influence of food on the bioavailability of metoprolol from an OROS system; a study in healthy volunteers. <i>Eur J Clin Pharmacol</i>. 1990;39(3):315-316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/2257873/pubmed" id="2257873" target="_blank">2257873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073535">
<a name="32073535"></a>Viigimaa M, Vlachopoulos C, Doumas M, et al; European Society of Hypertension Working Group on Sexual Dysfunction. Update of the position paper on arterial hypertension and erectile dysfunction. <i>J Hypertens</i>. 2020;38(7):1220-1234. doi:10.1097/HJH.0000000000002382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/32073535/pubmed" id="32073535" target="_blank">32073535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-vue.1">
<a name="vue.1"></a>Vue MH, Setter SM. Drug-induced glucose alterations part 1: drug-induced hypoglycemia. <i>Diabetes Spectrum</i>, 2011;24(3):171-177.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2865153">
<a name="2865153"></a>Westerlund A. Central nervous system side-effects with hydrophilic and lipophilic beta-blockers. <i>Eur J Clin Pharmacol</i>. 1985;(28)(suppl):73-76. doi:10.1007/BF00543714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/2865153/pubmed" id="2865153" target="_blank">2865153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133354">
<a name="29133354"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/29133354/pubmed" id="29133354" target="_blank">29133354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12548073">
<a name="12548073"></a>Wikstrand J, Andersson B, Kendall MJ, Stanbrook H, Klibaner M. Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure. <i>J Cardiovasc Pharmacol</i>. 2003;41(2):151-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/12548073/pubmed" id="12548073" target="_blank">12548073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1354194">
<a name="1354194"></a>Wynn RL. Dental Nonsteroidal Anti-inflammatory Drugs and Prostaglandin-Based Drug Interactions, Part Two. <i>Gen Dent</i>. 1992;40(2):104, 106, 108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/1354194/pubmed" id="1354194" target="_blank">1354194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7911769">
<a name="7911769"></a>Wynn RL. Epinephrine Interactions With Beta-Blockers. <i>Gen Dent</i>. 1994;42(1):16, 18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/7911769/pubmed" id="7911769" target="_blank">7911769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12463630">
<a name="12463630"></a>Yilmaz MB, Turhan H, Akin Y, Kisacik HL, Korkmaz S. Beta-blocker-induced psoriasis: a rare side effect--a case report. <i>Angiology</i>. 2002;53(6):737-739. doi:10.1177/000331970205300617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/12463630/pubmed" id="12463630" target="_blank">12463630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15234417">
<a name="15234417"></a>Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. <i>J Am Coll Cardiol</i>. 2004;44(1):105-108. doi:10.1016/j.jacc.2004.03.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metoprolol-pediatric-drug-information/abstract-text/15234417/pubmed" id="15234417" target="_blank">15234417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zimetbaum.1">
<a name="Zimetbaum.1"></a>Zimetbaum PJ, Wylie JV. Nonsustained ventricular tachycardia: Clinical manifestations, evaluation, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12605 Version 874.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
